AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06298370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal bupivacaine and morphine
Description: Patients will receive intrathecal bupivacaine and morphine without Pericapsular Nerve Group block. Intrathecal drugs will be administered at the L3-L4 intervertebral level by adding 10-15 mg bupivacaine with 100 μg of morphine. The patient controlled analgesia device with morphine will be adjusted as infusion: 0 ml/h, bolus: 1 mg/h, lockout period: 10 min.
Study NCT06298370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular nerve group block plus intrathecal bupivacaine and morphine
Description: Patients will undergo ultrasound-guided block using a linear or convex ultrasound probe in the supine position before intrathecal drugs. The block procedure will involve the use of a local anesthetic solution (10-20 ml of 0.25% bupivacaine and 2 mg dexamethasone) and a S22 Gauche 80 mm block needle. Subarachnoid block will be administered at the L3-L4 intervertebral level by adding 10-15 mg bupivacaine with 100 μg of morphine. The patient controlled analgesia device with morphine will be adjusted as infusion: 0 ml/h, bolus: 1 mg/h, lockout period: 10 min.
Study NCT05129891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide H
Description: Tablet given orally
Study NCT05129891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide I
Description: Tablet given orally
Study NCT05129891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 B
Description: Tablet given orally
Study NCT05129891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 C
Description: Tablet given orally
Study NCT05129891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 D
Description: Tablet given orally
Study NCT05129891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 E
Description: Tablet given orally
Study NCT05450549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL919
Description: Single doses
Study NCT05562635 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 5% polymer gel with CBD application
Description: Bilateral application of 5% polymer gel with CBD intraorally, on the masseter muscle
Study NCT05562635 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 10% polymer gel with CBD application
Description: Bilateral application of 10% polymer gel with CBD intraorally, on the masseter muscle
Study NCT05562635 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intervention
Description: Application of placebo without CBD
Study NCT06174532 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Traditional Medthod
Description: Before surgery, the patient's lower jawbone tumor is replicated using a 3D-printed original model without adjustments. Then, the model undergoes manual modification by drilling and adjusting the jawbone model at the tumor site using drills and manual instruments. Subsequently, the reconstructed model is formed preoperatively based on this modified model. During surgery, the patient isn't guided by surgical guides, and the incision lines are relatively dependent on the surgeon. Additionally, while fixing the remaining bone after the sectioning, the surgeon uses pre-bent fixation plates made earlier to assist in stabilizing the bone.
Study NCT06174532 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual surgical planning
Description: Before surgery, the patient's lower jawbone is 3D-printed, designed to remove the tumor mass, and create a suitable margin for reconstructive plate bending. Subsequently, the reconstruction plate is pre-bent preoperatively based on this model. During surgery, the patient is guided by specific surgical guiding tools: cutting guides. Additionally, while fixing the remaining bone after sectioning, the surgeon is assisted by bone fixation instruments to stabilize the alignment of the two bone fragments according to anatomical structure and then proceeds to use pre-bent reconstruction plates to secure the bone.
Study NCT05450549 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single doses
Study NCT06051292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast method
Description: Fast decremental catheter volume titration will be applied and optimal filling volume will be determined according to the measurements
Study NCT06051292 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional method
Description: Conventional catheter volume titration will be applied and optimal filling volume will be determined according to the measurements
Study NCT06450171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GRAIL Galleri Test
Description: A multi-cancer early detection (MCED) blood test.
Study NCT04712838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: Group A subjects were given oral F1 、F2 and F3 version SHR0302
Study NCT04712838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: Group B subjects were given oral F1 、F3 and F2 version SHR0302
Study NCT04712838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: Group C subjects were given oral F2 、F1 and F3 version SHR0302
Study NCT04712838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: Group D subjects were given oral F2 、F3 and F1 version SHR0302
Study NCT04712838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: Group E subjects were given oral F3 、F1 and F2 version SHR0302
Study NCT04712838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: Group F subjects were given oral F3 、F2 and F1 version SHR0302
Study NCT05423873 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Gentle Cleansing Lotion, Revision Skincare
Description: Gentle cleansing lotion to be used by study participants twice daily
Study NCT04809714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction with Delfi Tourniquet System Cuff
Description: Postoperative rehabilitation will occur up to twice a day for 5 days a week for 2 weeks using a Delfi tourniquet system blood pressure cuff with a limb occlusion pressure (LOP) of 60-100%. For each physical therapy session, participants will undergo therapy following a standardized protocol of 3-5 difference exercises each with 4 sets total in addition to NMES.
Study NCT04809714 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Post-operative Physical Therapy
Description: The control group with undergo a post-op therapy protocol that mirrors that of the intervention group except that they will use a Delfi tourniquet system blood pressure cuff with a limb occlusion pressure (LOP) of only 10%. Participants will use a neuromuscular electrical stimulation device operating at a sub-therapeutic level.
Study NCT05535920 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: LOKELMA 5 GM Powder for Oral Suspension
Description: Patients will use Lokelma supplementation on off-dialysis days (4 days/week) while receiving hemodialysis with 3.0 K+/2.5 Ca++ mEq dialysate bath. The individual starting dose will be 5.0 grams, and may be titrated weekly in 5.0 gram increments up to 15.0 grams to maintain K+ between 4.0 and 5.5 mEq/L.
Study NCT06144398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single Use Bronchoscope
Description: The interventional procedure is performed with a single use bronchoscope.
Study NCT06144398 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Bronchoscope
Description: The interventional procedure is performed with a standard bronchoscope.
Study NCT05532163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: Administered as specified in the treatment arm
Study NCT05591768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Monopolar radiofrequency
Description: In monopolar group : . Inferomedial, superomedial, and superolateral GN branches of the patients were identified with ultrasonography, and a 22 Gauge, 10 cm radiofrequency (RF) cannula with a 10 mm active tip was advanced to the targeted nerves under fluoroscopy guidance. The location of the RF cannula was visualized by anteriorposterior and lateral images. Sensory stimulation was applied at 50 Hz to determine the nerve position. Since the sensory stimulation threshold must be \< 0.6 V, nerve position was tested with the absence of fasciculation in the relevant area of the lower extremity upon 2.0 V stimulation at 2 Hz.
Study NCT05591768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency
Description: a similar technique will be used to insert the canula, except that, instead of one cannula two cannulae (approximately 10 mm apart) apart) will be inserted and no manipulation of cannulae was done to stimulate the target nerve as done in MRFA Target areas were similar to monopolar technique Each nerve will be ablated for 90 s in both the groups. All procedures were done by one pain physician who had more then 10 years' experience of radiofrequency procedures.
Study NCT05853939 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation
Description: Repetitive TMS targeted by neuronavigation to left lower visual field of primary visual cortex. Randomized to 10 Hz or 1 Hz on different treatment days. Stimulation at 110% of phosphene threshold, or 110% resting motor threshold if phosphenes not detectable. 1 Hz: 1000 pulses total over 1000 seconds. 10 Hz: 1000 pulses over 10 10 second pulse trains, with 50 second intertrain intervals
Study NCT05853939 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: Repetitive TMS targeted by neuronavigation to left lower visual field of primary visual cortex. Randomized to 10 Hz or 1 Hz on different treatment days. Stimulation at 110% of phosphene threshold, or 110% resting motor threshold if phosphenes not detectable. 1 Hz: 1000 pulses total over 1000 seconds. 10 Hz: 1000 pulses over 10 10 second pulse trains, with 50 second intertrain intervals
Study NCT06326229 — intervention group
Intervention type: OTHER
Intervention: ICF entities assessment
Description: A visual analog scale will be used by the participants to evaluate the relevance of the ICF entities in relation to their musculoskeletal condition. The scale will range from 0 (no problem) to 100 (complete problem).
Study NCT06586021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aortoseal Endostapling System
Description: Aortoseal Endostapling System
Study NCT06672393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10374 6mg tablets
Description: Specified dose of HS-10374 tablets administered orally QD on specified days
Study NCT06672393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HS-10374 6mg tablets
Description: Specified dose of HS-10374 tablets administered orally QD on specified days
Study NCT06672393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HS-10374-matched placebo tablets
Description: Specified dose of HS-10374-matched placebo tablets administered orally QD on specified days
Study NCT06672965 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: anti-stress supplement
Description: The anti-stress supplement was developed to provide relief from anxiety and depression levels.Subjects were given 60 capsules of calming supplement (30-day supply) and instructed to take two capsules each day orally with water.
Study NCT06672965 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects were given 60 capsules of placebo (30-day supply) and instructed to take two capsules each day orally with water.
Study NCT06671886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-trigger
Description: The NCCP Intervention is multicomponent. First, the investigators will apply the e-trigger and calculate FIB-4, and second, will educate and train PACT personnel on how to deal with trigger positive patients as well as make treatment recommendations within an inter-professional team. The e-trigger will be generated every 3 months. The effectiveness of the trigger will be assessed using the outcomes previously mentioned.
Study NCT06671041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative Free eye drop
Description: Participants were required to use a lubricating eye drop
Study NCT06671470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-1139 tablets
Description: Oral dose 20 mg
Study NCT06671470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor Tablets
Description: Oral dose 90 mg twice daily
Study NCT06671743 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal treatment
Description: History of presenting illness will be recorded and vitality testing will be done in addition to pre-operative radiograph.~Patient will read and sign the consent form. Pre-operative pain score will be recorded using visual analogue scale. The patient will take the preoperative medication 1 hour prior to the procedure.~The patient will receive 1 cartridge of LA with inferior alveolar nerve block (2% lidocaine 1:80000) and a rubber dam will be used for isolation.~Access cavity will be prepared and working length will be determined. Cleaning and shaping of the root canal system will be performed followed by obturation using a standardized protocol followed by final coronal restoration.~Postoperative pain score will be recorded at the 6, 12, 24, and 48 hours using visual analogue pain scale.
Study NCT06671743 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Root canal treatment
Description: History of presenting illness will be recorded and vitality testing will be done in addition to pre-operative radiograph.~Patient will read and sign the consent form. Pre-operative pain score will be recorded using visual analogue scale. The patient will take the preoperative medication 1 hour prior to the procedure.~The patient will receive 1 cartridge of LA with inferior alveolar nerve block (2% lidocaine 1:80000) and a rubber dam will be used for isolation.~Access cavity will be prepared and working length will be determined. Cleaning and shaping of the root canal system will be performed followed by obturation using a standardized protocol followed by final coronal restoration.~Postoperative pain score will be recorded at the 6, 12, 24, and 48 hours using visual analogue pain scale.
Study NCT06671743 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal treatment
Description: History of presenting illness will be recorded and vitality testing will be done in addition to pre-operative radiograph.~Patient will read and sign the consent form. Pre-operative pain score will be recorded using visual analogue scale. The patient will take the preoperative medication 1 hour prior to the procedure.~The patient will receive 1 cartridge of LA with inferior alveolar nerve block (2% lidocaine 1:80000) and a rubber dam will be used for isolation.~Access cavity will be prepared and working length will be determined. Cleaning and shaping of the root canal system will be performed followed by obturation using a standardized protocol followed by final coronal restoration.~Postoperative pain score will be recorded at the 6, 12, 24, and 48 hours using visual analogue pain scale.
Study NCT06671340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorzagliatin
Description: chronic treatment with dorzagliatin for 4 weeks (50mg twice daily or 75mg twice daily, oral)
Study NCT06671925 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strengthening COnnections to Overcome Pain (SCOOP)
Description: Each week for 7 weeks, SCOOP intervention group participants will watch a brief video on the study website teaching a pain management or social connectedness skill and have a session with a community health worker, where they will receive support with behavioral goal-setting related to pain management and/or social connections. Participants will be screened for unmet social needs and connected to appropriate resources.
Study NCT06692595 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: digital PCR
Description: digital PCR quantification of subgingival plaque samples
Study NCT06693596 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Group 2: Conservative management (follow-up)
Description: A standardised transabdominal examination is performed, including color or power Doppler examination. Transvaginal ultrasonography can be performed in sexually active adolescents with consent. Transrectal examination is also acceptable for younger patients who are not sexually active. All the variables required for the Simple Rules, simple descriptors and ADNEX model are assessed.~Before entering ultrasound information about the tumour and getting model results, the ultrasound examiner' s diagnosis (benign, borderline, malignant; specific diagnosis) based on subjective assessment is recorded. Results based on Simple Rules, simple descriptors and ADNEX model are documented as well.~If the adnexal mass is seen and if the decision is to manage the adnexal mass conservatively, the patient will be re-scanned at 6 weeks (maximal range 6-8 weeks), 3 months (+/- 2 weeks) and 12 months (maximal range 10-14 months)
Study NCT06693596 — intervention group
Intervention type: PROCEDURE
Intervention: Group 1: Surgical management
Description: A standardised transabdominal examination is performed, including color or power Doppler examination. Transvaginal ultrasonography can be performed in sexually active adolescents with consent. Transrectal examination is also acceptable for younger patients who are not sexually active. All the variables required for the Simple Rules, simple descriptors and ADNEX model are assessed.~Before entering ultrasound information about the tumour and getting model results, the ultrasound examiner' s diagnosis (benign, borderline, malignant; specific diagnosis) based on subjective assessment is recorded. Results based on Simple Rules, simple descriptors and ADNEX model are documented as well.~If the patient requires surgery, no further ultrasound scans will be required.
Study NCT06044623 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CDK 4/6 inhibitors
Description: Either Palbociclib, Ribociclib or Abemaciclib
Study NCT05278403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality and video games
Description: Use of a software in stroke patients' rehabilitation.
Study NCT05278403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurological physiotherapy
Description: Application of conventional physical therapy techniques.
Study NCT06044623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CDK 4/6 inhibitors
Description: Either Palbociclib, Ribociclib or Abemaciclib
Study NCT06044623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDK 4/6 inhibitors
Description: Either Palbociclib, Ribociclib or Abemaciclib
Study NCT06044623 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Endocrine therapy
Description: Either Letrozole, Anastrozole, Exemestane or Fulvestrant in combination with CDK 4/6-inhibitor
Study NCT06044623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine therapy
Description: Either Letrozole, Anastrozole, Exemestane or Fulvestrant in combination with CDK 4/6-inhibitor
Study NCT06044623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Either Letrozole, Anastrozole, Exemestane or Fulvestrant in combination with CDK 4/6-inhibitor
Study NCT05335174 — intervention group
Intervention type: DEVICE
Intervention: Device: HemoSphere monitor and Acumen IQ sensor.
Description: Patients will be placed on this monitor for the duration of study in the PACU. Followed by 30-day phone call to record cardiovascular complications.
Study NCT05243017 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: intra-striatal rAAV5-miHTT
Description: One time MRI-guided stereotaxic infusion of rAAV5-miHTT into the brain
Study NCT05209737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trendelenburg position
Description: A 10-degree head-down position will be used in this group
Study NCT05209737 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Semirecumbent position
Description: A 30-degree head-up position will be used in this group
Study NCT06276075 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation, the Erigo®Pro table, motor imagery
Description: 66 stroke patients were randomly assigned to three groups (22 people each) with different therapy (conventional, with the addition of Erigo®Pro and enriched with motor imagery). The therapy duration was two weeks. Patients underwent assessment before and after completion of therapy. The study used the Trunk Stability Test, Berg Balance Scale to assess balance, as well as the Riablo device to measure static balance. Additionally, an evaluation of the superficial tension of the transverse abdominis and multifidus muscles was conducted.
Study NCT06005831 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sandbag
Description: The standard sandbag used in our clinic, 20 × 20 × 3 cm3 in dimensions and 3 kg in weight
Study NCT05338450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clemastine Fumarate
Description: 4 mg of Clemastine Fumarate twice daily (8mg/day) orally for 6 months (180 days)
Study NCT05338450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo equivalent to experimental arm
Study NCT05489458 — intervention group
Intervention type: PROCEDURE
Intervention: Resection
Description: Type A BR-PDAC patients who had a favorable tumor/vascular structures relationship confirmed during surgical exploration underwent resection.
Study NCT05489458 — intervention group
Intervention type: PROCEDURE
Intervention: No Resection
Description: Type A BR-PDAC patients who did not have a favorable tumor/vascular structures relationship confirmed during surgical exploration did not undergo resection.